drugset / Trial / NCT05587621
Intensive Lipid-lowering in Patients With STEMI and NSTEMI (Germany on Target)
RandomizedParallel-groupOpen-labelPrevention
Summary
Intensive Lipid-Lowering Therapy guided by a cloud-based Software System (CLIMEDO GmbH) improves (European Society of Cardiolofgy/European Atherosclerosis Society) ESC/EAS-guideline recommended LDL-cholesterol target attainment and adherence in patients with ST-Elevation Myocardial (STEMI) and Non-ST-Elevation Myocardial Infarctions (NSTEMI).
Timeline
- Start
- 2024-04-01
- Primary completion
- 2026-04-30
- Completion
- 2026-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Alirocumab | Monoclonal antibody | — | — |
| Comparator | Bempedoic acid | Small molecule | — | — |
| Comparator | Evolocumab | Monoclonal antibody | — | — |
| Comparator | Ezetimibe | Unknown | — | — |
| Comparator | Inclisiran | Small interfering RNA (siRNA) | — | — |